Ropinirole hydrochloride for amyotrophic lateral sclerosis: a single-center, randomized, double-blind, placebo-controlled phase 1/2a feasibility trial

Published: 21 April 2023| Version 1 | DOI: 10.17632/jsfcx3vz8s.1
Contributor:
Satoru Morimoto

Description

These data are the deposited supplemental information for the article entitled "Ropinirole hydrochloride for amyotrophic lateral sclerosis: a single-center, randomized, double-blind, placebo-controlled phase 1/2a feasibility trial" by Morimoto and Takahashi et al. in Cell Stem Cell.

Files

Institutions

Keio Gijuku Daigaku - Shinanomachi Campus

Categories

Drug Discovery, Clinical Trial, Induced Pluripotent Stem Cell, Amyotrophic Lateral Sclerosis, Dopamine Receptor Agonist

Funding

Japan Agency for Medical Research and Development

JP22bm0804003, JP20ek0109395, JP20ek0109329, JP22ek0109493, JP22wm0425009

Japan Society for the Promotion of Science

JP22K15736, JP21H05273, JP22K07500, JP20H00485, JP21H05273, JP16H06277

K Pharma, Inc.

Uehara Memorial Foundation

YUKIHIKO MIYATA MEMORIAL TRUST FOR ALS RESEARCH

Okasan-Kato Foundation Research Grant

Yoshio Koide Grant, Japan ALS Association

Intramural Research Grant for Neurological Psychiatric Disorders from National Centre of Neurology and Psychiatry (NCNP)

Licence